Intensity-modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with non-small cell lung cancer.


Journal

Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 04 05 2020
revised: 14 07 2020
accepted: 11 09 2020
pubmed: 24 9 2020
medline: 15 5 2021
entrez: 23 9 2020
Statut: ppublish

Résumé

Intensity-modulated proton therapy (IMPT) is sensitive to uncertainties from patient setup and proton beam range, as well as interplay effect. In addition, respiratory motion may vary from cycle to cycle, and also from day to day. These uncertainties can severely degrade the original plan quality and potentially affect patient's outcome. In this work, we developed a new tool to comprehensively consider the impact of all these uncertainties and provide plan robustness evaluation under them. We developed a comprehensive plan robustness evaluation tool that considered both uncertainties from patient setup and proton beam range, as well as respiratory motion simultaneously. To mimic patients' respiratory motion, the time spent in each phase was randomly sampled based on patient-specific breathing pattern parameters as acquired during the four-dimensional (4D)-computed tomography (CT) simulation. Spots were then assigned to one specific phase according to the temporal relationship between spot delivery sequence and patients' respiratory motion. Dose in each phase was calculated by summing contributions from all the spots delivered in that phase. The final 4D dynamic dose was obtained by deforming all doses in each phase to the maximum exhalation phase. Three hundred (300) scenarios (10 different breathing patterns with 30 different setup and range uncertainty scenario combinations) were calculated for each plan. The dose-volume histograms (DVHs) band method was used to assess plan robustness. Benchmarking the tool as an application's example, we compared plan robustness under both three-dimensional (3D) and 4D robustly optimized IMPT plans for 10 nonrandomly selected patients with non-small cell lung cancer. The developed comprehensive plan robustness tool had been successfully applied to compare the plan robustness between 3D and 4D robustly optimized IMPT plans for 10 lung cancer patients. In the presence of interplay effect with uncertainties considered simultaneously, 4D robustly optimized plans provided significantly better CTV coverage (D A comprehensive plan robustness evaluation tool was successfully developed and benchmarked for plan robustness evaluation in the presence of interplay effect, setup and range uncertainties. The very high efficiency of this tool marks its clinical adaptation, highly practical and versatile nature, including possible real-time intra-fractional interplay effect evaluation as a potential application for future use.

Identifiants

pubmed: 32964474
doi: 10.1002/mp.14491
pmc: PMC7722083
mid: NIHMS1632044
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5428-5440

Subventions

Organisme : NCI NIH HHS
ID : K25 CA168984
Pays : United States
Organisme : Arizona Biomedical Research Commission
Organisme : Lawrence W. and Marilyn W. Matteson Fund for Cancer Research
Organisme : NCI NIH HHS
ID : K25CA168984
Pays : United States
Organisme : Kemper Marley Foundation

Informations de copyright

© 2020 American Association of Physicists in Medicine.

Références

J Appl Clin Med Phys. 2019 Jul;20(7):15-27
pubmed: 31112371
Med Phys. 2009 Jul;36(7):3059-71
pubmed: 19673205
Radiother Oncol. 2012 Jul;104(1):45-51
pubmed: 22560714
J Appl Clin Med Phys. 2017 Sep;18(5):29-35
pubmed: 28681976
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):523-533
pubmed: 26725727
Med Phys. 2012 Jun;39(6):3089-101
pubmed: 22755694
Med Phys. 2019 Dec;46(12):5434-5443
pubmed: 31595521
J Appl Clin Med Phys. 2017 Jul;18(4):76-83
pubmed: 28503916
Med Phys. 2018 Nov;45(11):5293-5304
pubmed: 30203550
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):380-6
pubmed: 23462423
Ann Transl Med. 2020 Sep;8(18):1198
pubmed: 33241047
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):479-489
pubmed: 29550033
Biomed Res Int. 2014;2014:485067
pubmed: 24524077
Med Phys. 2013 Feb;40(2):021709
pubmed: 23387732
Phys Med Biol. 2012 Feb 7;57(3):591-608
pubmed: 22222720
Phys Med Biol. 2005 Nov 7;50(21):5089-104
pubmed: 16237243
Phys Med Biol. 2012 May 7;57(9):N131-43
pubmed: 22504160
Pract Radiat Oncol. 2015 Mar-Apr;5(2):e77-86
pubmed: 25413400
J Cancer Ther. 2014 Feb;5(2):198-207
pubmed: 25506501
Med Phys. 2009 Jan;36(1):149-63
pubmed: 19235384
Med Phys. 2016 Jun;43(6):2807-2820
pubmed: 27277029
Med Phys. 2013 May;40(5):051711
pubmed: 23635259
Phys Med Biol. 2002 Jul 7;47(13):2203-20
pubmed: 12164582
Radiother Oncol. 2016 Nov;121(2):328-334
pubmed: 27817945
Med Phys. 2017 Oct;44(10):5081-5088
pubmed: 28777447
Phys Med Biol. 2003 Jan 7;48(1):45-62
pubmed: 12564500
Radiat Oncol. 2008 Oct 14;3:34
pubmed: 18854012
Med Phys. 2012 Feb;39(2):1079-91
pubmed: 22320818
Phys Med Biol. 2019 Apr 23;64(9):095005
pubmed: 30893664
Med Phys. 2003 Jun;30(6):1254-63
pubmed: 12852551
Med Phys. 2019 Nov;46(11):4755-4762
pubmed: 31498885
J Appl Clin Med Phys. 2018 Nov;19(6):140-148
pubmed: 30328674
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819887182
pubmed: 31755362
Br J Radiol. 2016;89(1060):20150431
pubmed: 26838950
Phys Med Biol. 2008 Mar 21;53(6):1689-700
pubmed: 18367797
Med Phys. 2019 Jan;46(1):382-393
pubmed: 30387870
Phys Med Biol. 2006 Jul 21;51(14):3517-31
pubmed: 16825746
Med Phys. 2020 Feb;47(2):745-752
pubmed: 31758864
Med Phys. 2019 Oct;46(10):4676-4684
pubmed: 31376305
Phys Med Biol. 2006 May 21;51(10):2567-83
pubmed: 16675870
Med Phys. 2016 Mar;43(3):1111-8
pubmed: 26936698
Med Phys. 2011 Mar;38(3):1672-84
pubmed: 21520880
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):181-193
pubmed: 31987967
Phys Med Biol. 2013 Jun 21;58(12):4137-56
pubmed: 23689035
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):216-223
pubmed: 27084643
Pract Radiat Oncol. 2014 Nov-Dec;4(6):e259-68
pubmed: 25407877
Med Phys. 2020 Mar;47(3):909-916
pubmed: 31880819
Med Phys. 2013 Jun;40(6):061702
pubmed: 23718581
J Appl Clin Med Phys. 2006 Winter;7(1):77-85
pubmed: 16518319
Med Phys. 2017 Jan;44(1):28-36
pubmed: 28044325
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1250-8
pubmed: 18823717
Med Phys. 2019 Jan;46(1):5-14
pubmed: 30339270
Phys Med Biol. 2018 Nov 12;63(22):22TR02
pubmed: 30418942
Radiat Oncol. 2019 Feb 7;14(1):30
pubmed: 30732657
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1229-38
pubmed: 18313530
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):357-66
pubmed: 19660879
Pract Radiat Oncol. 2016 Nov - Dec;6(6):e269-e275
pubmed: 27025166
Phys Med Biol. 2008 Feb 21;53(4):1027-42
pubmed: 18263956
Med Phys. 2014 Feb;41(2):021721
pubmed: 24506612
Phys Med Biol. 2017 Jul 31;62(16):6595-6609
pubmed: 28635614
Med Phys. 2018 Jan;45(1):460-469
pubmed: 29148570
World J Clin Oncol. 2014 Oct 10;5(4):568-75
pubmed: 25302161
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1015-22
pubmed: 20615629
Phys Med Biol. 2019 Feb 05;64(4):045002
pubmed: 30625459
Adv Radiat Oncol. 2019 Aug 21;5(3):450-458
pubmed: 32529140
Pract Radiat Oncol. 2014 Nov-Dec;4(6):384-91
pubmed: 25407859
Med Phys. 2003 Jan;30(1):88-97
pubmed: 12557983
Phys Med Biol. 2007 May 21;52(10):2755-73
pubmed: 17473350
Med Phys. 2005 Apr;32(4):874-89
pubmed: 15895570
Phys Med Biol. 2005 Oct 21;50(20):4853-62
pubmed: 16204877
Med Phys. 2018 Jul 16;:
pubmed: 30014478
Phys Med Biol. 2011 Nov 21;56(22):7257-71
pubmed: 22037710
Phys Med Biol. 2017 Mar 21;62(6):2486-2504
pubmed: 28240218
Phys Med Biol. 2011 Oct 21;56(20):6563-81
pubmed: 21937770
Med Phys. 2017 Dec;44(12):6138-6147
pubmed: 28976574
Radiother Oncol. 2019 Jul;136:185-189
pubmed: 31015123
Phys Med Biol. 1992 Jan;37(1):223-34
pubmed: 1311106
Phys Med Biol. 2008 Feb 21;53(4):1043-56
pubmed: 18263957
Phys Med Biol. 2005 Jun 21;50(12):2887-905
pubmed: 15930609
Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):576-82
pubmed: 24074932
Phys Med Biol. 2009 Jul 21;54(14):N283-94
pubmed: 19550002

Auteurs

Jie Shan (J)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Yunze Yang (Y)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Steven E Schild (SE)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Thomas B Daniels (TB)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

William W Wong (WW)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Mirek Fatyga (M)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Martin Bues (M)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Terence T Sio (TT)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Wei Liu (W)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH